Celularity Inc. (NASDAQ:CELU - Get Free Report) shares traded up 7.4% on Tuesday . The company traded as high as $2.33 and last traded at $2.33. 79,403 shares changed hands during trading, a decline of 76% from the average session volume of 332,284 shares. The stock had previously closed at $2.17.
Wall Street Analyst Weigh In
Separately, Wall Street Zen downgraded Celularity from a "hold" rating to a "sell" rating in a research note on Thursday.
View Our Latest Research Report on CELU
Celularity Stock Performance
The stock has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $1.99. The company has a market capitalization of $54.84 million, a PE ratio of -0.86 and a beta of 0.61.
Celularity (NASDAQ:CELU - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($1.50) by $0.91. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%. The company had revenue of $18.13 million during the quarter, compared to the consensus estimate of $5.20 million.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Keynote Financial Services LLC increased its holdings in shares of Celularity by 90.1% during the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company's stock valued at $52,000 after acquiring an additional 11,863 shares during the last quarter. C V Starr & Co. Inc. acquired a new position in shares of Celularity during the 4th quarter valued at about $1,589,000. Biltmore Family Office LLC acquired a new position in shares of Celularity during the 4th quarter valued at about $73,000. Acadian Asset Management LLC acquired a new position in shares of Celularity during the 1st quarter valued at about $34,000. Finally, Two Sigma Investments LP acquired a new position in shares of Celularity during the 4th quarter valued at about $93,000. Institutional investors and hedge funds own 19.02% of the company's stock.
About Celularity
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Featured Articles
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
